Division of Pharmaceutics and Pharmacology, College of Pharmacy and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, United States.
Kidney and Urinary Tract Research Center, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, Ohio, United States.
Am J Physiol Renal Physiol. 2024 Sep 1;327(3):F426-F434. doi: 10.1152/ajprenal.00147.2024. Epub 2024 Jul 11.
The biology of the cyclin-dependent kinase-like (CDKL) kinase family remains enigmatic. Contrary to their nomenclature, CDKLs do not rely on cyclins for activation and are not involved in cell cycle regulation. Instead, they share structural similarities with mitogen-activated protein kinases and glycogen synthase kinase-3, although their specific functions and associated signaling pathways are still unknown. Previous studies have shown that the activation of CDKL5 kinase contributes to the development of acute kidney injury (AKI) by suppressing the protective SOX9-dependent transcriptional program in tubular epithelial cells. In the current study, we measured the functional activity of all five CDKL kinases and discovered that, in addition to CDKL5, CDKL1 is also activated in tubular epithelial cells during AKI. To explore the role of CDKL1, we generated a germline knockout mouse that exhibited no abnormalities under normal conditions. Notably, when these mice were challenged with bilateral ischemia-reperfusion and rhabdomyolysis, they were found to be protected from AKI. Further mechanistic investigations revealed that CDKL1 phosphorylates and destabilizes SOX11, contributing to tubular dysfunction. In summary, this study has unveiled a previously unknown CDKL1-SOX11 axis that drives tubular dysfunction during AKI. Identifying and targeting pathogenic protein kinases holds potential for drug discovery in treating acute kidney injury. Our study, using novel germline knockout mice, revealed that Cdkl1 kinase deficiency does not affect mouse viability but provides protection against acute kidney injury. This underscores the importance of Cdkl1 kinase in kidney injury and supports the development of targeted small-molecule inhibitors as potential therapeutics.
CDK 样激酶家族的生物学仍然是一个谜。与它们的命名相反,CDKL 不依赖于细胞周期蛋白进行激活,也不参与细胞周期调控。相反,它们与丝裂原活化蛋白激酶和糖原合成酶激酶-3具有结构相似性,尽管它们的具体功能和相关信号通路仍不清楚。以前的研究表明,CDKL5 激酶的激活通过抑制管状上皮细胞中 SOX9 依赖性转录程序,有助于急性肾损伤 (AKI) 的发展。在本研究中,我们测量了所有五种 CDKL 激酶的功能活性,发现除了 CDKL5 之外,CDKL1 在 AKI 期间也在管状上皮细胞中被激活。为了探索 CDKL1 的作用,我们生成了一种生殖系敲除小鼠,在正常情况下没有表现出任何异常。值得注意的是,当这些小鼠受到双侧缺血再灌注和横纹肌溶解的挑战时,它们被发现免受 AKI 的影响。进一步的机制研究表明,CDKL1 磷酸化并使 SOX11 不稳定,导致管状功能障碍。总之,这项研究揭示了一个以前未知的 CDKL1-SOX11 轴,它在 AKI 期间驱动管状功能障碍。鉴定和靶向致病蛋白激酶有可能为治疗急性肾损伤的药物发现提供新的途径。我们的研究使用新型生殖系敲除小鼠表明,Cdkl1 激酶缺乏不会影响小鼠的生存能力,但能提供对急性肾损伤的保护。这突显了 Cdkl1 激酶在肾损伤中的重要性,并支持开发靶向小分子抑制剂作为潜在的治疗方法。